

MammaTyper[®]

Molecular subtyping test for breast cancer

Early, accurate diagnosis to help guide better treatment decisions

Pathologist



Reproducibility
Sensitivity

Surgeon



Optimisation
Reduced surgery

Oncologist



Reliability, Time

Nurse



Reduced Side Effects

Patient



Speed, Trust

MammaTyper® is a molecular subtyping test for breast cancer.



Breast cancer is the most prevalent cancer in women worldwide¹. Survival is related to advances in early detection, accurate diagnosis and effective treatment of the disease.



What is MammaTyper®?

MammaTyper® is the first real innovation in breast cancer subtyping for decades. Applying 21st century techniques to breast cancer subtypes, ensuring that every tissue sample is tested reliably, accurately, and quickly. The result? A solid foundation to build a treatment plan, giving every woman the best chance of beating breast cancer. With the use of MammaTyper®, a reverse transcription, quantitative real-time polymerase chain reaction (RT-qPCR) test for breast cancer subtyping, you can ensure that every tissue sample is tested reliably, accurately, and quickly. Molecular subtyping is essential for accurate treatment decisions and gives an indication of prognosis.

Reducing Time to Diagnosis

For treatment of invasive breast cancer, the best chance of recovery relies on patients receiving the best treatment for their own, individual case, as quickly as possible. This is dependent on accurate subtyping of the tumour, a process which has essentially remained unchanged for over half a century and is vulnerable to inaccuracies. This is becoming even more obvious with the release of new treatment pathways that rely on highly accurate diagnostic processes to work effectively.

Improving survival rates

With early diagnosis of breast cancer – Almost all women with breast cancer survive their disease for 5 years or more, if diagnosed at the earliest stage².

Accurate molecular subtyping using MammaTyper® drives understanding of the genetic subtype of each individual tumour and leads to faster diagnostic decisions. This provides a solid foundation on which to build a treatment plan, giving every patient the best chance of beating breast cancer.

Strong Diagnostic Decisions with MammaTyper®


Molecular subtyping is vital for the selection of the correct treatment options, and using MammaTyper® provides strong diagnostic foundations on which to build treatment decisions.

1. <https://www.who.int/news-room/fact-sheets/detail/breast-cancer> Accessed August 2023

2. <https://digital.nhs.uk/data-and-information/publications/statistical/cancer-survival-in-england#latest-statistics> Accessed August 2023

MammaTyper® is a molecular diagnostic test for quantitative determination of the four key biomarkers used in the subtyping of breast cancer.

The St. Gallen International Expert Panel recommends the use of 4 biomarkers for the molecular sub-typing of breast cancer.³



These are all key biomarkers in the evaluation of breast cancer tumours. The combination of biomarker results allows the assessment of the different St. Gallen breast cancer subtypes which are key parameters for treatment decisions.

Definition of Breast Cancer Surrogate Subtypes (St Gallen³)


Breast Cancer Subtypes	ER	PR	HER2	Ki-67
Luminal A - like	Pos	Pos	Neg	Neg
Luminal B - like (HER2 negative)	Pos	Pos/Neg*	Neg	Pos/Neg*
Luminal B - like (HER2 positive)	Pos	Pos/Neg	Pos	Pos/Neg
HER2 positive (non luminal)	Neg	Neg	Pos	Pos/Neg
Triple negative (ductal)	Neg	Neg	Neg	Pos/Neg

*With the exception of the combination of PR pos and Ki-67 neg = Luminal A-Like.

Simple, Fast Workflow

In the laboratory, MammaTyper® provides simultaneous quantitative determination of the 4 key biomarkers, used in the subtyping of breast cancer - from start to finish in <6 hours.

MammaTyper® Workflow




3. Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert consensus on the Primary Therapy of Early Breast Cancer 2013 Goldhirsch, A.Albain, Kathy S. et al. Annals of Oncology, Volume 24, Issue 9, 2206 - 2223.

*FFPE Fixed-Formalin Paraffin-Embedded
**IFU Instructions for Use

Convenient MammaTyper[®] Report Generator software:

Export of mRNA expression data.
Calculation and assessment of results.



The advantages of choosing MammaTyper[®]

Feature	Benefit
Fast set up and turnaround time	Quick turnaround for patient results, and reporting
Easy to Use	No need for dedicated equipment, works on already established lab instrumentation
Accurate & Precise	Quantitative detection with high precision and reproducible accuracy
Clinically Validated	Over 30 independent publications and poster presentations sharing clinical performance
Flexibility	True open assay system with 8 different instruments already validated
Automated Reporting	Web-based report generation makes results interpretation simple and fast

To order the MammaTyper® test
or to learn more about Cerca Biotech,
please contact your local distributor.



To talk about the MammaTyper® test
or for further information,
please get in touch:

info@cercabiotech.com
www.cercabiotech.com

 <https://www.linkedin.com/company/cerca-biotech/>
 @cercabiotech
 cerca_biotech

Cerca Biotech GmbH • Alexandrinenstr. 1a • D-10969 • Berlin, Germany

© 2023 Cerca Biotech. All rights reserved. MammaTyper® and CercaTest® are registered trademarks of Cerca Biotech